Global investor Corinth Group invests USD100m in Morepen Laboratories
Global investment group Corinth Group has made a USD100 million investment in Morepen Group, Delhi (India), a 36-year-old, listed Indian pharmaceutical company with two USFDA approved facilities. At an Extraordinary General Meeting (EGM) held yesterday through video conferencing, the shareholders approved the direct investment of USD32.50 million in Morepen’s equity.